Trials / Terminated
TerminatedNCT04489940
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bintrafusp alfa | Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death. |
Timeline
- Start date
- 2020-10-12
- Primary completion
- 2022-01-27
- Completion
- 2022-07-08
- First posted
- 2020-07-28
- Last updated
- 2023-04-10
- Results posted
- 2023-04-10
Locations
45 sites across 6 countries: United States, Belgium, France, Italy, Russia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04489940. Inclusion in this directory is not an endorsement.